JNJ

239.47

+0.54%↑

UNH

276.79

+3.23%↑

TMO

542.02

-2.02%↓

ABT

109.96

+0.76%↑

ISRG

489.76

+1.33%↑

JNJ

239.47

+0.54%↑

UNH

276.79

+3.23%↑

TMO

542.02

-2.02%↓

ABT

109.96

+0.76%↑

ISRG

489.76

+1.33%↑

JNJ

239.47

+0.54%↑

UNH

276.79

+3.23%↑

TMO

542.02

-2.02%↓

ABT

109.96

+0.76%↑

ISRG

489.76

+1.33%↑

JNJ

239.47

+0.54%↑

UNH

276.79

+3.23%↑

TMO

542.02

-2.02%↓

ABT

109.96

+0.76%↑

ISRG

489.76

+1.33%↑

JNJ

239.47

+0.54%↑

UNH

276.79

+3.23%↑

TMO

542.02

-2.02%↓

ABT

109.96

+0.76%↑

ISRG

489.76

+1.33%↑

Search

Heron Therapeutics Inc

Deschisă

SectorSănătate

1.24 -0.8

Rezumat

Modificarea prețului

24h

Curent

Minim

1.18

Maxim

1.26

Indicatori cheie

By Trading Economics

Venit

-15M

-17M

Vânzări

1M

38M

Marjă de profit

-45.783

Angajați

122

EBITDA

-12M

-14M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+240.91% upside

Dividende

By Dow Jones

Următoarele câștiguri

26 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

37M

253M

Deschiderea anterioară

2.04

Închiderea anterioară

1.24

Sentimentul știrilor

By Acuity

33%

67%

77 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bearish Evidence

Heron Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 feb. 2026, 23:57 UTC

Câștiguri

Naver Has Record Year Despite Weaker Final Quarter

5 feb. 2026, 23:45 UTC

Acțiuni populare

Stocks to Watch: Amazon, Coty, Gen Digital, Roblox

5 feb. 2026, 22:26 UTC

Câștiguri

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9% -- Update

5 feb. 2026, 22:00 UTC

Câștiguri

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9%

5 feb. 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

5 feb. 2026, 23:47 UTC

Market Talk

Nikkei May Fall After U.S. Tech Stock Drops -- Market Talk

5 feb. 2026, 23:43 UTC

Market Talk

Gold Falls on Spillover Impact From Cryptocurrencies' Selloff -- Market Talk

5 feb. 2026, 23:37 UTC

Market Talk

Glencore Shares Look Cheap After Failed Takeover Talks -- Market Talk

5 feb. 2026, 23:20 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 5th Update

5 feb. 2026, 23:11 UTC

Market Talk

Amazon CEO Confident in Return on $200B Investment -- Market Talk

5 feb. 2026, 23:09 UTC

Câștiguri

Naver 2025 Net KRW1.820T Vs. Net KRW1.932T >035420.SE

5 feb. 2026, 23:08 UTC

Câștiguri

Naver 2025 Oper Pft KRW2.208T Vs. Pft KRW1.979T >035420.SE

5 feb. 2026, 23:07 UTC

Câștiguri

Naver 2025 Rev KRW12.035T Vs. KRW10.738T >035420.SE

5 feb. 2026, 23:03 UTC

Market Talk
Câștiguri

REA's Update Looks Negative Despite A$200M Buyback -- Market Talk

5 feb. 2026, 23:03 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bitcoin Booster's $12 Billion Loss Headlines Crypto's Worst Day Since 2022 Crash -- WSJ

5 feb. 2026, 23:00 UTC

Câștiguri

Naver 4Q Net Profit Missed FactSet-Compiled Consensus

5 feb. 2026, 23:00 UTC

Câștiguri

Naver 4Q Net KRW164.60B Vs. Net KRW514.00B >035420.SE

5 feb. 2026, 22:59 UTC

Câștiguri

Naver 4Q Oper Pft KRW610.60B Vs. Pft KRW542.00B >035420.SE

5 feb. 2026, 22:59 UTC

Câștiguri

Naver 4Q Rev KRW3.195T Vs. KRW2.886T >035420.SE

5 feb. 2026, 22:52 UTC

Câștiguri

Alphabet Stock Is Taking a Hit After Strong Earnings. Don't Panic. -- Barrons.com

5 feb. 2026, 22:45 UTC

Câștiguri

Amazon Stock Falls Sharply on Earnings. Spending Continues to Soar. -- Barrons.com

5 feb. 2026, 22:37 UTC

Market Talk

Woolworths's Profit Margin Likely Faces 2Q Squeeze -- Market Talk

5 feb. 2026, 22:11 UTC

Câștiguri

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9% -- Update

5 feb. 2026, 22:03 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 4th Update

5 feb. 2026, 22:01 UTC

Câștiguri

Reddit Stock Jumps on Earnings. CFO Cites Modest AI Spending. -- Barrons.com

5 feb. 2026, 21:59 UTC

Market Talk
Achiziții, Fuziuni, Preluări

What's Next For Rio Tinto, Glencore After Deal Talks Fail? -- Market Talk

5 feb. 2026, 21:51 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Saylor's Strategy Posts $12 Billion Quarterly Loss on Bitcoin Selloff -- WSJ

5 feb. 2026, 21:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Basic Materials Roundup: Market Talk

5 feb. 2026, 21:49 UTC

Câștiguri

Why Google's Bad News Was Good News for Broadcom and Nvidia -- Barrons.com

5 feb. 2026, 21:45 UTC

Câștiguri

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9%

Comparație

Modificare preț

Heron Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

240.91% sus

Prognoză pe 12 luni

Medie 4.5 USD  240.91%

Maxim 6 USD

Minim 3 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHeron Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

2

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.0001 / 2.42Suport & Rezistență

Termen scurt

Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

77 / 352 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat